Comparative Pharmacology
Head-to-head clinical analysis: FYLNETRA versus RELEUKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYLNETRA versus RELEUKO.
FYLNETRA vs RELEUKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYLNETRA (filgrastim-ayow) is a granulocyte colony-stimulating factor (G-CSF) analog that binds to the G-CSF receptor on neutrophils and their precursors, stimulating proliferation, differentiation, and functional activation of neutrophils.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
3.6 mg/kg subcutaneously once daily for up to 14 days. Dose based on absolute neutrophil count.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (range 2–5 hours); supports daily dosing in most patients for myelosuppressive chemotherapy.
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
Renal (primarily, as unchanged drug and metabolites, minor biliary/fecal)
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor